Selected article for: "concentration dose and virus replication"

Author: Sandra De Meyer; Denisa Bojkova; Jindrich Cinati; Ellen Van Damme; Christophe Buyck; Marnix Van Loock; Brian Woodfall; Sandra Ciesek
Title: Lack of Antiviral Activity of Darunavir against SARS-CoV-2
  • Document date: 2020_4_8
  • ID: 679qfp2s_6
    Snippet: In this paper, the antiviral activity of DRV against SARS-CoV-2 was investigated in an in vitro model at clinically relevant concentrations. When DRV/c is taken at the indicated once-daily dose, the median trough plasma concentration of DRV was 3.4 µM (1875 ng/mL). (6) . This cell culture assay was shown to be suitable for antiviral assays. Productive viral infection takes place in this model with the number of SARS-CoV RNA molecules increasing .....
    Document: In this paper, the antiviral activity of DRV against SARS-CoV-2 was investigated in an in vitro model at clinically relevant concentrations. When DRV/c is taken at the indicated once-daily dose, the median trough plasma concentration of DRV was 3.4 µM (1875 ng/mL). (6) . This cell culture assay was shown to be suitable for antiviral assays. Productive viral infection takes place in this model with the number of SARS-CoV RNA molecules increasing continuously after infection, indicating that the virus undergoes full replicatory cycles (12) . Remdesivir (GS-5734), a nucleotide analog initially developed for Ebola virus disease, has shown to inhibit SARS-CoV-2 replication in vitro with an EC 50 equal to 0,770 µM (13) and was therefore used as a positive control.

    Search related documents:
    Co phrase search for related documents